662
  • About Us
    • About us
    • Our Team
    • Partnerships
  • Development Programs
    • Development Overview
    • Lead Assets
      • IHL-42X: Obstructive Sleep Apnoea
      • Psi-GAD: Psilocybin for anxiety
      • IHL-675A: Rheumatoid Arthritis
    • Secondary Assets
      • IHL-675A: Inflammatory bowel disease
      • IHL-675A: Lung inflammation
      • IHL-216A: Concussion and TBI
      • CannQuit-N: Nicotine Addiction
      • CannQuit-O: Opioid Addiction
      • ReneCann: Vitiligo, Psoriasis, Eczema
  • Investors
    • Stock Information
    • News & Media
    • SEC Filings
    • Presentations
    • Historic Announcements
  • Corporate Governance
  • Contact Us
662

Incannex is a global leader in medicinal cannabinoid compounds and psychedelic therapies, with 28 FDA compliant R&D programs.

  • About us
  • Clinical Trials
  • Investors
  • News
  • Contact Us

Level 23, Rialto South Tower,
525 Collins Street,
Melbourne VIC 3000
admin@incannex.com.au

© 2024 Incannex All rights reserved